Bristol Myers Squibb presented the positive Phase III results on its already approved Opdivo-Yervoy combo at ESMO over the ...
Besides stomach cancer, the FDA also raised a similar concern for PD-1 drugs in first-line esophageal squamous cell carcinoma ...
BMO Capital analyst Evan Seigerman maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) today and set a price target ...
The first undervalued wide-moat stock on our list is Bristol Myers Squibb. The drugmaker’s portfolio covers many therapeutic ...
Analyst Mohit Bansal from Wells Fargo maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) and keeping the price ...
The FDA issued draft guidance on oncology clinical trials, taking the first steps toward formalizing a position that it's ...
Bristol Myers Squibb (NYSE: BMY) has struggled to manage the loss of exclusivity now that some of its top-selling drugs are facing competition from generics. Disappointing results from the ...
Experts noted, however, there is insufficient evidence to determine which commercially available KRAS G12C inhibitor is the ...
Medpage Today on MSN13d
Second Malignancy Risk With CAR T-Cell Therapy on Par With Other TreatmentsCAR T-cell therapy carried a risk of second primary malignancy (SPM) that was no worse than that of other standard-of-care ...
Renal cancer, also known as kidney cancer, is a disease where malignant (cancer) cells form in the tissues of the kidneys. Smoking, obesity, hypertension, and chronic kidney disease contribute to ...
Tocilizumab -- an interleukin (IL)-6 receptor inhibitor -- was approved by the FDA in 2017 for the treatment of severe or ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback